American Healthcare REIT Soars 1.86% on Analyst Upgrades

American Healthcare (AHR) surged 1.86% today, reflecting a strong performance in the market.

Could you please clarify if you meant to ask about the performance of buying AHR shares after they reached a recent high and holding for 1 week over the past 5 years? If so, we can use the BackTest tool to analyze this strategy.

Recent analyst activities have shown changes in ratings and price targets for American Healthcare REIT (AHR). Several analysts have raised their ratings and price targets, with recommendations ranging from "Overweight" to "Buy" and "Sector Outperform." The average 12-month price target has increased significantly by 17.68% to $40.4.

On June 30, 2025, Scotiabank initiated coverage on American Healthcare REIT with a "Sector Outperform" rating and a price target of $42. This new coverage could influence investor sentiment and impact stock performance.

The company reported a solid revenue growth rate of approximately 8.22% as of March 31, 2025, surpassing expectations and outperforming peers in the real estate sector, which could positively affect investor outlook and stock valuation.

Despite positive revenue growth, American Healthcare REIT faces challenges with a negative net margin of -1.26%, a low return on equity (ROE) of -0.3%, and a return on assets (ROA) of -0.15%, which could raise concerns about profitability and operational efficiency among investors.

On June 30, 2025, American Healthcare REIT declared a quarterly cash distribution of $0.25 per share for the quarter ending June 30, 2025, which could attract income-focused investors and influence stock demand.